Journal
GENE THERAPY
Volume 18, Issue 3, Pages 220-224Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/gt.2010.123
Keywords
anaplastic large cell lymphoma (ALCL); cell transfection; gene silencing; DNA minicircle
Categories
Funding
- Burroughs Welcome Fund
- National Institutes of Health (NIH) [K22CA113493, RO1A1054830]
- TMHRI CTS Award
Ask authors/readers for more resources
This work illustrates the utility of Minivector DNA, a non-viral, supercoiled gene therapy vector incorporating short hairpin RNA from an H1 promoter. Minivector DNA is superior to both plasmid DNA and small interfering RNA (siRNA) in that it has improved biostability while maintaining high cell transfection efficiency and gene silencing capacity. Minivector DNAs were stable for over 48 h in human serum, as compared with only 0.5 and 2 h for siRNA and plasmid, respectively. Although all three nucleic acids exhibited similar transfection efficiencies in easily transfected adhesion fibroblasts cells, only Minivector DNAs and siRNA were capable of transfecting difficult-to-transfect suspension lymphoma cells. Minivector DNA and siRNA were capable of silencing the gene encoding anaplastic lymphoma kinase, a key pathogenic factor of human anaplastic large cell lymphoma, and this silencing caused inhibition of the lymphoma cells. Based on these results, Minivector DNAs are a promising new gene therapy tool. Gene Therapy (2011) 18, 220-224; doi:10.1038/gt.2010.123; published online 21 October 2010
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available